Document 0102 DOCN M9650102 TI Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands. DT 9605 AU Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis,; Indiana 46285-1523, USA. SO J Med Chem. 1996 Jan 5;39(1):96-108. Unique Identifier : AIDSLINE MED/96136792 AB Noncoded D-amino acids have been designed to replace the quinaldic amide-asparaginyl moiety (P2/P3 ligand) found in several potent human immunodeficiency virus (HIV) protease inhibitors such as LY289612. The substituted nitrogen, optimally an N-methanesulfonyl moiety, served as a CH2CONH2 (asparagine side chain mimic), while the amino acid side chain became the backbone and P3 ligand of these novel inhibitors. Compounds derived from S-aryl-D-cysteine proved to be potent HIV protease inhibitors which also exhibited potent whole cell antiviral activity. Oxidation of the cysteines to the sulfoxide or sulfone oxidation states resulted in significant improvements in potency. For example, the compound derived from N-(methyl-sulfonyl)-2-S-naphthylcysteine sulfone, 17c, was a 3.5 nM inhibitor of HIV protease which inhibited the spread of virus in MT4 cells with an IC50 = 4.3 nM. Compounds 17c,g,i were found to be orally bioavailable in a rat model. DE Amino Acids/METABOLISM Animal Antiviral Agents/CHEMISTRY/*CHEMICAL SYNTHESIS/METABOLISM/ PHARMACOLOGY Biological Availability Cysteine/*ANALOGS & DERIVATIVES Drug Design Human HIV Protease/*METABOLISM HIV Protease Inhibitors/*CHEMICAL SYNTHESIS/METABOLISM/ PHARMACOLOGY HIV-1/*DRUG EFFECTS/ENZYMOLOGY Ligands Male Molecular Structure Nuclear Magnetic Resonance Protein Binding Rats Rats, Sprague-Dawley Spectrum Analysis, Mass Structure-Activity Relationship Sulfones/CHEMICAL SYNTHESIS/PHARMACOLOGY JOURNAL ARTICLE SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).